ArticleCurrent treatment options in neurology2014
Treatment options for thyroid eye disease.
Article in Current treatment options in neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 11 citations in OpenAlex.
- Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Treatment of ocular motor palsies.Current treatment options in neurology · 2015Article
- Virtual Surgical Planning for Orbital Reconstruction.Middle East African journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementPatients with thyroid eye disease (TED) experience hypertrophy of their extraocular muscles and an increase in intraorbital fat volume leading to eyelid retraction, proptosis, double vision, and optic nerve compression. These orbital changes are thought to be due to a cross-reaction of thyroid stimulating hormone (TSH) with antigens in the orbit. Therefore, the key to treatment is achievement of a euthyroid state in patients with abnormal thyroid function. Cigarette smoking is the strongest modifiable risk factor linked with progression and poor response to treatment. All TED patients should be counseled and offered help with smoking cessation. The treatment of TED symptoms must be customized to each patient, as the degree of orbital involvement can vary. During the active state, evaluation of sight-threatening compressive optic neuropathy and treatment of corneal exposure by an ophthalmologist is crucial to avoid irreversible damage. In most patients, local therapy with artificial tears, gels, and ointments can offer symptomatic relief of irritation and dryness. In addition, antioxidant therapy with selenium has been shown to improve quality of life in patients with mild orbital involvement. Some patients will require systemic oral or IV steroids at the onset of an active inflammatory state. However, approximately one third of patients will not be responsive to steroid therapy alone. In these patients, the addition of orbital radiation or use of immune modulation has shown value. Orbital decompression surgery should be considered for cases of vision-threatening optic neuropathy despite maximal medical therapy. Approximately 3-6 months after cessation of the active state and stabilization of symptoms, rehabilitative treatment may be offered. Treatment is offered in a 3-stage surgical approach with orbital decompression surgery, followed by strabismus surgery for any resultant binocular diplopia, and finally eyelid surgery to address eyelid retraction. Meanwhile, symptomatic diplopia may be addressed with monocular patching or prisms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.